In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. David Gaffney, Dr. Carien Creutzberg, and Dr. Anuja Jhingran to discuss this month's special issue on radiation oncology. Dr. Gaffney, MD, PhD, Senior Director of Clinical Research, is Professor and Vice-Chair of the University of Utah (U of U) Department of Radiation Oncology. Dr. Gaffney is a distinguished clinician and a long-standing leader in clinical research, and he is also a past president of the...
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. David Gaffney, Dr. Carien Creutzberg, and Dr. Anuja Jhingran to discuss this month's special issue on radiation oncology. Dr. Gaffney, MD, PhD, Senior Director of Clinical Research, is Professor and Vice-Chair of the University of Utah (U of U) Department of Radiation Oncology. Dr. Gaffney is a distinguished clinician and a long-standing leader in clinical research, and he is also a past president of the American Brachytherapy Society. Dr. Carien Creutzberg is Professor of Radiation Oncology at Leiden University Medical Center, the Netherlands. She specializes in research and treatment of gynecological cancers and has been initiator and principal investigator of the four PORTEC trials and the TransPORTEC consortium. She is current chair of the GCIG Endometrial Cancer Committee and past Council member of ESGO and IGCS. Dr. Anuja Jhingran is a Professor of Radiation Oncology in the Section of Gynecology at The University of Texas MD Anderson Cancer Center. She is the present treasure/secretary for IGCS. She is highly active in GCSC, GCIC, ASCO, and SGO. Her passion is to improve treatment for all women with gynecological cancer throughout the world and she does this through mentoring physicians in underserved regions throughout world.
Highlights:
Stereotactic body radiation therapy (SBRT) is useful in gynecological cancers.
Brachytherapy improves survival in cervix cancer.
Image guidance in radiation oncology decreases morbidity.
Patients with small volume disease and long disease-free interval may be good candidates for SBRT.
Immunotherapy can be combined with radiation therapy.
